Overview

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Status:
Terminated

Trial end date:
2009-04-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine how effective azacitidine, MGCD0103, and the combination of azacitidine and MGCD0103 are in treating AML or MDS in people over 60 years of age.

Phase:

Phase 2

Details

Lead Sponsor:

Mirati Therapeutics Inc.

Treatments:

Azacitidine
Histone Deacetylase Inhibitors
Mocetinostat